Health and Healthcare
IPO Filing Floodgates: Aegerion Pharmaceuticals, Inc. (AEGR)
Published:
Last Updated:
Aegerion Pharmaceuticals, Inc. filed Tuesday for an initial public offering of up to $86.25 million in securities for filing purposes. It has the proposed ticker of "AEGR" on NASDAQ, and the underwriting group consists of Piper Jaffray, Thomas Weisel partners, Lazard Capital Markets, and Collins Stewart, LLC.
Aegerion is an emerging biotech company focused on small-molecule therapeutics to treat cardiovascular and metabolic disease. Its lead product candidates, AEGR-733 and AEGR-427, are microsomal triglyceride transfer protein inhibitors, or MTP-Is, which limit secretion of cholesterol and triglycerides from both the intestine and liver.
24/7 Wall St. will have to do some research here because this IPO had originally been filed back in March 2007, but was withdrawn from registration in June.
If you wish to join our open email distribution list we often provide more detailed IPO and spin-off coverage. These are frequently lead-ins to our subscriber-based "Special Situation Investing Newsletter" where we cover buyouts, spin-offs, back-door plays into IPO’s, reorganizations, and more.
Jon C. Ogg
November 21, 2007
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
